UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024 07:46 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024 07:05 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor...
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
September 03, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that five posters across its development programs will be included at the Society for the...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
August 30, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
August 08, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year Galafold® Q2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti® + Opfolda® Q2 Revenue of $15.9M, up 44% from Q1 2024 Raising 2024...
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 30, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2024,...
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global...
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
June 04, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
May 09, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold® Guidance on Continued Strong Demand ...
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
May 08, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2024 Health Care...